- Home
- SYM vs PTGX Comparison
SYM vs PTGX Comparison
Compare SYM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYM
- PTGX
- Stock Information
- Founded
- SYM 2005
- PTGX 2006
- Country
- SYM United States
- PTGX United States
- Employees
- SYM N/A
- PTGX N/A
- Industry
- SYM Industrial Machinery/Components
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- SYM Industrials
- PTGX Health Care
- Exchange
- SYM Nasdaq
- PTGX Nasdaq
- Market Cap
- SYM 3.0B
- PTGX 2.7B
- IPO Year
- SYM N/A
- PTGX 2016
- Fundamental
- Price
- SYM $24.66
- PTGX $38.80
- Analyst Decision
- SYM Buy
- PTGX Strong Buy
- Analyst Count
- SYM 13
- PTGX 8
- Target Price
- SYM $42.50
- PTGX $54.63
- AVG Volume (30 Days)
- SYM 2.3M
- PTGX 663.7K
- Earning Date
- SYM 02-03-2025
- PTGX 02-25-2025
- Dividend Yield
- SYM N/A
- PTGX N/A
- EPS Growth
- SYM N/A
- PTGX N/A
- EPS
- SYM N/A
- PTGX 2.68
- Revenue
- SYM $1,788,179,000.00
- PTGX $323,795,000.00
- Revenue This Year
- SYM $31.70
- PTGX $441.08
- Revenue Next Year
- SYM $28.07
- PTGX N/A
- P/E Ratio
- SYM N/A
- PTGX $14.38
- Revenue Growth
- SYM 51.94
- PTGX 125.73
- 52 Week Low
- SYM $17.11
- PTGX $21.43
- 52 Week High
- SYM $52.20
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- SYM 42.90
- PTGX 41.13
- Support Level
- SYM $23.21
- PTGX $38.04
- Resistance Level
- SYM $25.03
- PTGX $39.86
- Average True Range (ATR)
- SYM 1.48
- PTGX 1.50
- MACD
- SYM -0.00
- PTGX -0.07
- Stochastic Oscillator
- SYM 39.16
- PTGX 22.28
About SYM Symbotic Inc.
Symbotic Inc is an automation technology company that develops technologies to improve operating efficiencies in modern warehouses. The group develops, commercializes, and deploys innovative, end-to-end technology solutions that dramatically improve supply chain operations. Symbotic also automates the processing of pallets and cases in large warehouses or distribution centers for some of the retail and wholesale companies in the world. The company operates in two geographical regions the United States and Canada. Key revenue is generated from the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.